Clinical Trials Logo

Filter by:
NCT ID: NCT04551898 Completed - Covid19 Clinical Trials

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Start date: December 2, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19

NCT ID: NCT04551872 Completed - Obesity Clinical Trials

RESILIENCE: Personalizing Cardiovascular Health

RESILIENCE
Start date: September 22, 2020
Phase: N/A
Study type: Interventional

Obesity is a rapidly growing epidemic that is associated with the development of cardiovascular disease (CVD). However, some individuals with obesity appear to be resistant to CVD, and other individuals demonstrate resilience to obesity and CVD risk factors. The investigator's overall objective is to understand factors contributing to the heterogeneity of CVD resistance and resilience among individuals with obesity at Duke.

NCT ID: NCT04551820 Completed - Cholecystectomy Clinical Trials

Study of Peri-operative and Acute Outcomes After Robotic-assisted Cholecystectomy

SPARC
Start date: August 5, 2020
Phase:
Study type: Observational

A multi-center retrospective chart review of short-term outcomes associated with robotic-assisted cholecystectomies performed during regular hours and after-hours.

NCT ID: NCT04551677 Completed - Healthy Volunteers Clinical Trials

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Start date: September 16, 2020
Phase: Phase 4
Study type: Interventional

Primary Objective: To provide serum samples (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to Center for Biologics Evaluation and Research (CBER) for further analysis by the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA) to support formulation recommendations for subsequent influenza vaccines. In addition, serum samples from adult participants may be further analyzed by the Sponsor to assess breadth of immune response induced by the study vaccines.

NCT ID: NCT04551599 Completed - Healthy Clinical Trials

A Study of the Effects of Food and Age on Danicopan

Start date: February 21, 2020
Phase: Phase 1
Study type: Interventional

This will be an open-label, 2-part study. Part 1 will be a randomized, 2-sequence, 2-period crossover, food-effect study in healthy young adult participants. Part 2 will be a 1-period age-effect study in healthy elderly male participants.

NCT ID: NCT04551586 Completed - Healthy Clinical Trials

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Start date: June 26, 2020
Phase: Phase 1
Study type: Interventional

This will be an open-label, 3-sequence, 3-period crossover study in healthy adult participants to assess the relative bioavailability of ACH-0145228 when administered as an immediate release tablet versus powder-in-capsule.

NCT ID: NCT04551534 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers

Start date: June 1, 2017
Phase: Phase 1
Study type: Interventional

This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study conducted in three parts.

NCT ID: NCT04551352 Completed - Uveal Melanoma Clinical Trials

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Start date: October 28, 2020
Phase: Phase 1
Study type: Interventional

This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC) administrations of RO7293583 with or without obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive melanomas who have progressed on standard of care (SOC) treatment, are intolerant to SOC, or are non-amenable to SOC. This study will include an initial single participant dose-escalation part one followed by a multiple participant dose-escalation part two with the possibility of expansion.

NCT ID: NCT04551339 Completed - Healthy Clinical Trials

Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19

ZnCOVID-19
Start date: September 28, 2020
Phase: N/A
Study type: Interventional

The purpose of this research study is to look at high dose zinc versus multivitamin micronutrient supplementation to support immune health in the setting of the COVID-19 pandemic.

NCT ID: NCT04551196 Completed - Pain, Postoperative Clinical Trials

Management of Post-Tonsillectomy Pain in Pediatric Patients

Start date: September 28, 2020
Phase: Phase 3
Study type: Interventional

Single-center, randomized, open-label, non-inferiority treatment pilot study to evaluate the effectiveness of a combined acetaminophen and ibuprofen regimen for treatment of post-operative tonsillectomy pain in the pediatric population. 100 children undergoing tonsillectomy will be randomized to receive either a combined acetaminophen and ibuprofen regimen dosed every 6 hours or an alternating regimen of acetaminophen and ibuprofen dosed every 3 hours.